/
SIGA Technologies, Inc. is referred to throughout this report as SIGA, the Company, we or us. The Company sells its lead product, TPOXX ( oral TPOXX , also known as "tecovirimat," "Tecovirimat-SIGA," or "TEPOXX (tecovirimat)" in certain international markets), to the U.S.
25.06% operating margin is above average. ROIC at 7.97%. Note that capital returns lag the margin, the business may be capital-intensive despite high margins.
Revenue declined 31.8% YoY. Margins deteriorated 25.4pp alongside, both lines moving the wrong way.
Free cash flow declined 12% versus the prior year, cash generation momentum has weakened. ROIC dropped from 25.63% to 7.97%, capital efficiency is deteriorating.
Profitability & Returns
Revenue (TTM)
$94M
▼ -31.8% YoY
Net Income (TTM)
$20M
▼ -60.7% YoY
Op. Margin
22.01%
▼ -25.4pp YoY
ROIC
7.28%
▼ -17.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$27M
▼ -11.5% YoY
Op. Cash Flow (TTM)
$28M
▼ -10.8% YoY
Net Debt
-$145M
Net Cash Position
Cash & Equiv.
$146M
5Y CAGR: -5.4%
5Y CAGR: -9.6%
Continue Research